The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

Advanced wound care market projected to exceed $15 billion globally by 2030 PERTH, Australia, Feb. 12, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: ...

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

The BC Cancer Foundation has launched a $6.8 million fundraising campaign to expand provincial immunotherapy research program ...

Robot Corp. , a leader in consumer robots, today announced that the company will host its fourth-quarter and full-year 2024 earnings conference call on Wednesday, March 12. Prior to the call, iRobot ...

The pharmaceutical industry is highly regulated and maintains strict standards of precision. Embracing automation and the advanced digital tools conceived through the principles of Pharma 4.0 aim to ...

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.